Optimal Design of Drug-Drug Interaction Studies for the GLP-1 Receptor Agonist Drug Class for Weight Management: Closing a Potential Data Gap

被引：0
|
作者：
Weber, Elijah [1 ]
Trivedi, Ashit [2 ]
Barbour, April M. [1 ]
机构：
[1] AstraZeneca, Clin Pharmacol & Quantitat Pharmacol, Clin Pharmacol & Safety Sci, R&D, Gaithersburg, MD USA
[2] AstraZeneca, Clin Pharmacol & Quantitat Pharmacol, Clin Pharmacol & Safety Sci, R&D, Waltham, MA USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2025年
关键词：
clinical pharmacology study design; drug-drug interaction; gastric-emptying delay; GLP-1; RA; oral contraceptive;
D O I：
10.1002/jcph.70020
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：3
相关论文
共 35 条
  • [1] Drug-Drug Interactions of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, with Warfarin and Digoxin in Healthy Subjects
    Bush, Mark
    Scott, Rhona
    Zhi, Hui
    Watanalumlerd, Prapoch
    Lewis, Eric
    DIABETES, 2011, 60 : A601 - A601
  • [2] The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag
    Gnerre, Carmela
    Segrestaa, Jerome
    Seeland, Swen
    Aanismaa, Paivi
    Pfeifer, Thomas
    Delahaye, Stephane
    de Kanter, Ruben
    Ichikawa, Tomohiko
    Yamada, Tetsuhiro
    Treiber, Alexander
    XENOBIOTICA, 2018, 48 (07) : 704 - 719
  • [3] Drug Design of GLP-1 Receptor Agonists: Importance of In Silico Methods
    Sharma, Smriti
    Bhatia, Vinayak
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (08) : 1015 - 1024
  • [4] GLP-1 agonist-based therapies: An emerging new class of antidiabetic drug with potential cardioprotective effects
    Sulistio, Melanie
    Carothers, Curtis
    Mangat, Mandeep
    Lujan, Mike
    Oliveros, Rene
    Chilton, Robert
    CURRENT ATHEROSCLEROSIS REPORTS, 2009, 11 (02) : 93 - 99
  • [5] GLP-1 agonist-based therapies: An emerging new class of antidiabetic drug with potential cardioprotective effects
    Melanie Sulistio
    Curtis Carothers
    Mandeep Mangat
    Mike Lujan
    Rene Oliveros
    Robert Chilton
    Current Atherosclerosis Reports, 2009, 11 : 93 - 99
  • [6] Assessment of drug-drug interaction potential with EDP-305, a farnesoid X receptor agonist, in healthy subjects
    Ahmad, Alaa
    Adda, Nathalie
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (09): : 2146 - 2158
  • [7] A Drug and Disease Model for Lixisenatide, a GLP-1 Receptor Agonist in Type 2 Diabetes
    Wilkins, Justin J.
    Dubar, Michel
    Sebastien, Bernard
    Laveille, Christian
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (03): : 267 - 278
  • [8] Assessment of Potential Drug-Drug Interactions for Novel Oral Melanocortin-1 Receptor Agonist Dersimelagon
    Ogasawara, Akihito
    Ide, Ryosuke
    Inoue, Shinsuke
    Tsuda, Minoru
    Teng, Renli
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2025, 13 (01):
  • [9] GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects?
    Zweck, Elric
    Roden, Michael
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (02): : 89 - 90
  • [10] Preliminary in vitro approach to evaluate the drug-drug interaction potential of EST73502, a dual μ-opioid receptor partial agonist and σ1 receptor antagonist
    Ayet, Eva
    Yeste, Sandra
    Reinoso, Raquel F.
    Pretel, Maria Jose
    Balada, Ariadna
    Serafini, Maria Teresa
    XENOBIOTICA, 2021, 51 (05) : 501 - 512
1234